Current Report Filing (8-k)
May 15 2020 - 12:00PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of
the Securities Exchange Act 1934
Date of Report
(Date of earliest event reported): May 15, 2020
NEMAURA
MEDICAL INC.
(Exact name of
registrant as specified in charter)
Nevada
(State or other
jurisdiction of incorporation)
001-38355
|
|
46-5027260
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
57
West 57th Street
Manhattan,
NY
|
10019
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
|
+1
(646) 416-8000
|
N/A
(Former
name or former address, if changed since last report)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
[_] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant
to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[_] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock
|
NMRD
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07.
|
Submission of Matters
to a Vote of Security Holders.
|
On May 15, 2020, Nemaura Medical
Inc. (the “Company”) held its 2020 annual meeting of stockholders (the “Annual Meeting”) to vote on the
following matters:
1. Election of
Directors
Each of the following five nominees
was elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term
of one year, until the next annual meeting of stockholders and until their successors have been duly elected and have qualified.
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Dewan Fazlul Hoque Chowdhury
|
|
16,218,770
|
|
7,170
|
|
--
|
|
|
|
|
|
|
|
Bashir Timol
|
|
16,218,770
|
|
7,170
|
|
--
|
|
|
|
|
|
|
|
Thomas Moore
|
|
16,217,334
|
|
8,606
|
|
--
|
|
|
|
|
|
|
|
Dr. Salim Natha
|
|
16,217,234
|
|
8,706
|
|
--
|
|
|
|
|
|
|
|
Timothy Johnson
|
|
16,217,334
|
|
8,606
|
|
--
|
2. Approval of
Nemaura Medical Inc. 2020 Omnibus Incentive Plan
Stockholders approved the Nemaura
Medical Inc. 2020 Omnibus Incentive Plan, in accordance with the voting results listed below.
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
16,211,982
|
|
12,218
|
|
1,740
|
|
418,355
|
3. Ratification
of the Company’s Independent Auditors
Stockholders ratified the appointment
of Mayer Hoffman McCann P.C. as the independent auditors of the Company for the fiscal year ended March 31, 2020, in accordance
with the voting results listed below.
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
16,641,076
|
|
1,953
|
|
1,266
|
|
--
|
As previously reported, on April
2, 2020, the Company received a written notice (the “Notice”) from staff of Listing Qualifications of The Nasdaq Stock
Market LLC (“Nasdaq”) indicating that the Company had not complied with the requirements of Nasdaq Listing Rule 5620(a)
of Nasdaq’s listing rules due to its failure to hold an annual meeting of stockholders within 12 months of the end of the
Company’s fiscal year ended December 31, 2018. The Company believes that it has regained compliance with the Nasdaq Listing
Rules following the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: May 15, 2020
|
Nemaura Medical Inc.
|
|
|
|
By:
|
/s/ Dewan F. H. Chowdhury
|
|
Name:
Title:
|
Dewan F. H. Chowdhury
Chief Executive Officer
|
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024